Supplementary methods
We obtained peripheral blood samples from 59 rheumatoid arthritis (RA) patients who fulfilled the ACR2010 classification criteria for RA and had been followed up in the Helsinki University Hospital rheumatology outpatient clinic after RA diagnosis. Twelve patients suffering from acquired aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (hMDS) were recruited from the Helsinki University Hospital hematology clinic. We also used two female healthy controls (ages 18-22) as negative controls. All patients gave written informed consent and the declaration of Helsinki principles were followed. The ethical board of our institution approved the study. DNA was extracted from peripheral EDTA blood using magnetic bead-based method by Chemagic MSM1 according to manufacturer's protocol (PerkinElmer, Waltham, MA, USA). For AA/hMDS patients, we used bone-marrow mononuclear cells (MNC), except for one patient (MDS1), from whom we used peripheral whole-blood DNA.
To screen for clonal hematopoiesis (CH), we designed a custom sequencing panel based on the Illumina TruSeq Custom Amplicon technology (Illumina, San Diego, CA, USA). The panel was designed to cover the genes that are commonly mutated in healthy individuals and AA patients [1] [2] [3] [4] [5] [6] [7] [8] . Coding exons of 34 tumor suppressor genes and/or mutational hotspots were sequenced (Supplementary table 1 ; exact genomic coordinates provided as Supplementary Data). 250 base-pair amplicons were designed with Illumina Design Studio. The panel consisted of 583 amplicons.
Library preparation was performed from 250ng genomic DNA according to the manufacturer's instructions (Illumina TruSeq custom Amplicon v1.5 reference guide) with the exception that that the last normalization step was left out to allow exact quantification of the libraries. The sequencing libraries were quantified with Bioanalyzer DNA1000 -chip (Agilent Technologies, Santa Clara, CA, USA).
Sequencing was performed with the Illumina HiSeq2500 system with 150 paired-end (PE) reads (Rapid PE150). The average coverage for each amplicon is shown in Supplementary figure 1. After sequencing, the data was processed by an in-house bioinformatics pipeline, which has been described previously. 9 Bowtie 2 and GATK Indelrealigner were used for sequence alignment to the Hg19 reference genome. Bases with Phred score <20 were discarded. Variants with over 5 supporting reads, less than 2% noise, and positions passing a binomial test threshold p-value < 10 -5 were called.
• The ratio of the number of variant calls/number of all bases and quality sum/quality sum of all bases at the position was required to be at least 0.9.
• Variants that were called from only one strand (forward or reverse) even though sequencing was performed in that genomic area as paired-end sequencing were discarded.
• Variants with variant-allele frequency (VAF) >35% were discarded as germline variants. We also discarded all variants with a population frequency of over 1% (based on 1000 Genomes data), 10 and variants that occurred in more than 10 individuals in our dataset.
• Variants with read count<500, variant base count <20, along with variants which comprised less than 80% of all variant bases were discarded.
• Variants within 5 base pairs of a 5 base-pair homopolymer were discarded, as well as clearly mismapped variants (visually inspected in IGV).
The Ensembl GRch37 variant effect predictor 11 was used to annotate variants, including SIFT and Polyphen scores.
In this study, we consider clonal hematopoiesis as a process in which mutations provide cells some survival advantage 12 . Thus, we discarded all non-coding mutations and synonymous mutations from further analyses and required that the VAF must be at least 2%, as this has been suggested as a cutoff threshold for clonal hemaotpoeisis of indeterminate potential (CHIP) 13 . We did not require missense mutations to exist in cancer-gene databases or to harbor deleterious prediction scores in in silico analyses, because these strategies will cause underreporting of novel variants and over-reporting of known variants. The table shows details for all mutations that were identified in this study. All genomic coordinates and annotations are based on the GRCh37 reference genome. The mutations are shown in HGVS format. The amino-acid change for the mutation (AA change) is shown for the canonical transcript or for the transcript that had the most deleterious prediction for the protein structure. Canonical transcripts were defined as the transcript with the longest CCDS translation. The transcript from which the amino-acid changes were determined are also listed in the In an interaction model, the effect of CH and smoking were significant on lymphocyte counts in follow-up (CH*time*smoking), so patients were grouped according to smoking status and clonal hematopoiesis status. Although the effect of time was significant factor on lymphocyte counts in follow-up in different patient groups, the post-hoc tests were not significant in any group except in no CH, no smoking. Post-hoc tests were corrected for multiple comparisons with the Sidak method. Abbreviations: CH, clonal hematopoiesis; dg, diagnosis; ND, not determined (because n=2). The linear mixed model mean and confidence interval estimates for lymphocyte counts in follow-up time-points for each group are shown as back-transformed values. Post-hoc tests were corrected for multiple comparisons with the Sidak method. Abbreviations: CH, clonal hematopoiesis; CI, confidence interval; ND, not determined.
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Supplementary figure 2. Mutation VAF and treatment response.
AA1 had received cyclosporine A (CsA) and corticosteroids (CS) as first-line therapy for AA, and she was receiving them when two of the samples were obtained. However, she did not have response (NR) to the CsA+CS treatment. She received antithymocyte globulin (ATG), CsA, and CS some months later. In the sample that was obtained after the ATG treatment, the LAMB4 mutation could not be detected although it was detected in the previous two samples. She had a partial response (PR) to the ATG+CsA+CS treatment. Patients with RA had clinical information collected when they had received RA diagnosis. We collected the samples for sequencing 2-4 years after RA diagnosis, HAQ at dg but we tested the differences between patients with/without CH at diagnosis, because the situations at diagnosis are more comparable than follow-up parameters: after diagnosis, the patients received anti-rheumatic and antiinflammatory treatments with a goal for disease remission. Also, it is likely that the CH mutations were not restricted to the follow-up samples, but have existed already at diagnosis. Clinical parameters did not differ between patients with clonal hematopoiesis and patients without clonal hematopoiesis (Mann-Whitney test). Abbreviations: CH, clonal hematopoiesis as defined in this study; ESR, erythrocyte sedimentation rate; DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire.
mean MCV at follow-up time-points was significantly elevated from the diagnosis mean (p-values shown in the figure; Sidak correction for multiple comparisons). The plot shows medians and error bars represent the interquartile range. Abbreviations: CH, clonal hematopoiesis as defined in this study; Dg, diagnosis.
